Chitosan Plus

Chitosan Plus 1 Caps. cu: Chitosan 200 mg de la LipoSan Ultra, Psyillium Husk 200 mg, L-Carnitina Pura de (Baza) 200 mg, echivalent cu: L-Carnitina Tartrat 300 mg, Guar Gum 100 mg, Gymnema Sylvestre 50 mg.

1 Chitosan si Crom este un nou supliment nutritiv integrator efectiv in terapia de reducere a greutatii corporale.

2 Chitosan reduce greutatea corporala cu eficienta studiu randomizat, dublu-orb, placebo controlat, studiul a exminat solubilitatea si nivelul de scadere a greutatii corporale.

Chitosan Plus

Chitosan o cale de scadere a greutatii coporale

3. Chitosan Plus absoarbe de 4-6 ori greutate sa, capteaza grasimile la nivelul tractului digestiv, efect sinergetic ca acidul ascorbic

Chitosan de la LipoSan Ultra ® cu 30% mai multa capacitate de absorbtie a grasimilor in comparatie cu alte tipuri de Chitosan, deci: Discount 30%

- Cu albastru Chitosan Chinezesc cu densitate inalta - dupa 60 min. 70%,

- Cu verde Chitosan obisnuit - dupa 60 min.68%,

- Cu rosu Chitosan marca inregistrata LipoSan Ultra ^® - dupa 60 min. 99%

Chitosan marca inregistrata LipoSan Ultra ® - dupa 60 min. 99%

Viscozitatea de fibre solubile

4. La examinul de scintigrafie sa observat in imagine ca granulele microcristaline de Chitosan sau marit in stomac cu 50 %

5. Chitosan Plus: Un supliment nutritiv integrator efectiv impreuna cu o dieta hipocalorica la obezi cu hiperlipidemie

Chitosan supliment nutritiv la pacienti cu obezitate

6. Chitosan Plus: Un supliment nutritiv integrator efectiv cu Pectina de Mere

7. Chitosan indicat in vindecarea ranilor si alte aplicatii biomedicale

8. Reviu: Aplicatii cu Chitosan un natural, modern, produs Bio pentru secolul 21

9. Chitosan Plus un tratament efectiv de reducere a greutatii corporale in obezitate

Chitosan un tratament efectiv de reducere a greutatii corporale si a nivelului de colesterol

10. Chitosan evaluatie clinica biochimica pentru reducere a nivelului seric al colesterolului total in hipercolesterolemie la obezi cu Diabet tip 2

11. Exercitiu fizic de performanta moduleaza controlul glicemic la Diabet tip 2

12. Exercitiu fizic de performanta cu efect in reducerea greutatii corporale la femei sedentare supra-ponderale

13. Cantitatea exercitiilor fizice, influenteaza greutatea corporala, si obezitatea, studiu randomizat, dublu-orb, placebo controlat

14. Activitate imunologica antimicrobiala si antifungala la Chitosan si derivatii sai

15. Chitosan un tratament efectiv la pacienti cu insuficienta renala cronica, cu rezultate significante de reducere a nivelului seric al colesterolului total, acidului uric si creatininei

16. Crom Picolinat ca supliment nutritiv reduce greutatea corporala studiu randomizat, dublu-orb, placebo controlat

17. Crom si exercitiu fizic de performanta - cu efect la femei obeze

18. Efectul benefic de Crom pentru persoanele cu diabet, studiu randomizat, dublu-orb, placebo controlat la Crom Picolinat

Cercetare:	Ce zice oamenii de stiinta despre Crom Picolinat

19. Psyllium cu eficacitate in reducerea glicemiei la persoane cu diabet tip 2 si cu uz dietetic in hipercolesterolemie

20. Psyllium reduce valorile ale lipoproteinelor cu densitate joasa (colesterolul-LDL) la persoane cu hipercolesterolemie control meta analiza: de 8-ori

Producatori de colesterol	Colesterol in singe

21. Psyllium indicat ca tratament la copii cu hipercolesterolemie studiu randomizat, dublu-orb, placebo controlat

22. Psyllium indicat la colita ulceroasa studiu randomizat

23. Glucomannan in tratamentul la pacienti supraponderali cu osteoartrita

24. Glucomannan ca uz dietetic in tratamentul de obezitate severa si reducere a nivelului seric al colesterolului total

25. Folosirea de Glucomannan ca fibre alimentare de puritate inalta la copii cu obezitate studiu randomizat, dublu-orb, placebo controlat

Fibre alimentare cu Glucomannan reduce nivelul proteinei C-reactive (C-reactive protein - CRP) responsabila pentru bolile cardiovasculare

26. Glucomannan imbunatateste glicemia la diabetul zaharat tip 2 si alti factori de risk a bolilor coronariene, studiu randomizat, dublu-orb, placebo controlat

27. Actiunea de Glucomannan la pacientii cu constipatie cronica: studiu clinic multicentric

28. Guar Gum cu efect de reducere a nivelului seric al colesterolului total, hiperlipidemie in cadrul diabetului si creste fibrinoliza

29. Reviu: Guar Gum cu proprietati farmacologice si cu uz dietetic in hipercolesterolemie

30. Gymnema Sylvestre extract standardizat acid gimnemic cu noul peptid gurmarina inhiba substantele dulci din glucoza, sucroza, readuce echilibrul simtului gustativ

31. Gymnema Sylvestre extract standardizat acid gimnemic are actiune hipoglicemica de inhibare a glucozei in singe la diabetici

32. Posibilitatea de regenerare a celulelor Langerhans din pancreas prin acidul gimnemic din Gymnema sylvestre

Celulele Langerhans cu posibilitate de regenerare

33. L-Carnitina are efect de a reduce valorile ale lipoproteinelor cu densitate joasa (colesterolul-LDL)

34. L-Carnitina creste concentratia plasmatica a lipoproteinelor cu densitate inalta (colesterolul-HDL) si scade nivelul de trigliceride in hipertrigliceridemie

35. L-Carnitina indicat la pacienti cu dislipidemie

36. Acid Alfa lipoic cu efect de anti obezitate, inhiba in hipotalamus, activitatea protein kinaza -AMPK

Cercetare:

Declaratii a oamenilor de stiinta si cercetare despre Chitosan

37. Dr. Arnold Fox, cardiologist si autorul cartii: Dieta de blocare a grasimilor spune:
"Chitosan este o descoperire senzationala reduce grasimea, scade trigliceridele ajuta sa creasca colesterolul bun si controleaza apetitul la nivel normal"

38. Dr. Elizabeth Muss de la (Cornell University Medical College in Ithaca, N.Y.) spune:

" Chitosan o cale de scadere a greutatii coporale ieftina, eficienta, sigura si simpla", deci va propunem oferta ca: Set Cura de Slabire 2= 1 Cura de Slabire 700 mg, 30 buc., +1 Chitosan Plus 625 mg, 30 buc., economisiti cel mai mult - 1325 mg = 1,7 lei noi/zi prin: Oferta speciala!

Chitosan absoarbe grasimile in grame/zi

Graficul de mai sus: Chitosan si Vitamina C - 2 Ingrediente la pretul intre = 22800 lei/zi - 48000 lei/zi

Va rugam sa comparati: Oferta!

Chitosan Plus: Un complex de 9 Ingrediente = 0,8 lei noi/zi

Va propunem: Oferta! Set Cura de Slabire 2 = 1 Cura de Slabire 700 mg, 30 buc., + 1 Chitosan Plus 625 mg, 30 buc.

Economisiti cel mai mult - 1325 mg = 1,7 lei noi/zi prin:

Oferta speciala!

Acid Hidroxicitric (AHC) din 1g (Garcinia Cambogia) cu CitriMax ^® promoveaza:

Reducerea greutatii corporale

Distribuirea grasimii corporale - Waist-to-Hip-Ratio (WHR)

Cu cit este mai mare BMI cu atit riscul de infarct miocardic si accident vascular cerebral creste.

Studiile internationale arata ca factorul de risc = distribuirea grasimii corporale - Waist-to-hip-Ratio (WHT) care este o mai buna masurare a riscului de infarct si accident vascular cerebral.

La barbati: distribuirea grasimii corporale regiunea abdomenului, cu un risc marit de boli cardiovasculare

La femei: distribuirea grasimii corporale pe fese si coapse - obezitate gluteo-femurala, cu un risc marit de boli cardiovasculare

Pentru distribuirea grasimii corporale (WHR) se caracerizeaza = Raportul dintre Distribuirea grasimii corporale a taliei si distribuirea grasimii corporale a soldului

- La barbati: WHR este mai mare de 1

- La femei: WHR este mai mare de 0,85

- Riscul circumferintei abdominale incepe la barbati cu talia de 94 cm, iar la 102 cm se afla in zona de pericol, cu marirea valorilor de trigliceride, si cresterea colesterolului in singe, care sint facori de risc, infarct miocardic si accident vascular cerebral

Riscul circumferintei abdominale

- Riscul circumferintei abdominale incepe la femei cu talia de 80 cm, iar la 88 cm se afla in zona de pericol, cu marirea valorilor de trigliceride, si cresterea colesterolului in singe, care sint facori de risc, infarct miocardic si accident vascular cerebral

Masurarea grasimii corporale - Skinfold Caliper	Se masoara	grasimea corporala in %

 

Reducerea de: Hemoglobina glicozilata HbA1c

Tesutul adipos secreta: Citokine (Mediatori inflamatorii), un factor implicat in procesul de ateroscleroza ca factor de agregare plachetara, factor regulator al tensiunii si factor regulator al metabolizmului cu hormonul: Adiponectina un factor protector cardiovascular si un biomarker de risc.

Cu aparatul de masura a greutatii corporale si circumferinta abdominala se constata riscul bolilor metabolice: diabet zaharat tip 2, afectiuni cardiovasculare si accident vascular cerebral, recomandabil: Vitamina E Forte 400 UI

Circumferinta abdominala	Aparat de masura a greutatii corporale

La barbati cine are indexul masei corporale BMI mai mare de 30 kg/m²(Biomarker de sindrom metabolic) si o circumferinta abdominala mai mare de 102 cm este afectat grav.

La femei riscul creste deja la o circumferinta abdominala de 88 cm este afectat grav de a primi boli metabolice: diabet zaharat tip 2, afectiuni cardiovasculare si accident vascular cerebral, recomandabil: Vitamina E Forte 400 UI

Cu 4 ore de sport, pe saptamina si un consum zilnic mai mic de 30 % de acizi grasi, dintre care acizi grasi saturati mai putin de 10 % si 15 g/1000kcal-fibra dietetica (dietary fiber), recomandabil: Chitosan Plus, Cura de Slabire si

Set Cura de Slabire

Reducerea de masa corporala cu 10 kg reduce cu 3% Hemoglobina glicozilata HbA1c

39. Spirulina moduleaza apetitul datorita continutului de proteine 67% care eliberareaza substanta ciclica AMP si extractul de ceai verde stimuleaza termogeneza in obezitate, prin administrarea cu 30 min. inainte de masa

- Cercetatori de la Institutul Francez INSERM au publicat in revista „Cell Metabolism “ au explicat cum proteinele reduce apetitul, si foamea.
- Cercetatorii Francezi au constatat o alimentatie bogata in proteine, da semnalul activitatii genetice de crestere a glucozei pe care ficatul trimete semnalul catre cerebral de stopare alimentara.
- Cecetatorul Gilles Mithieux presupune eliberarea substanzei ciclice AMP care activeaza gena de producere a glucozei.

40. Ceai Verde cu continutul de catechine stimuleaza termogeneza in obezitate prin inhibarea enzimei catecol-o-metiltransferaza (COMT).

Un studiu stiintific cu Christian Roberts de la Universitatea din California arata ca in numai trei saptamini se inbunatateste valorile sanatatii, la 31 de barbati cu obezitate severa:

Majoritatea obezilor sufera de sindrom metabolic, hipertensiune arteriala, valorile de colesterol inalte, dezechilibru glucozic, creste numarul de cazuri cu diabet tib 2.

- Schimbarea regimului alimentar, reducere calorica, cu fibre dietetice, program sportiv de 45 min. - 60 min.

- La ateroscleroza regimul alimentar si programul sportiv trebuie prelungit pe lunga durata.

Bibliografie-Referinte:

Informatii din bibliografia electronica la tema: Nutritie si sanatate

1. Girola M, De Bernardi M, Contos S et al: Dose effect in lipid-lowering activity of a new dietary integrator (chitosan, Garcinia cambogia extract and chrome). Acta Toxicol Ther 1996; 17(1):25-40.
- Giustina A, Ventura P. Weight-reducing regimens in obese subjects: effects of a new dietary fiber integrator. Acta Toxicol Ther. 1995; 16:199-214.
- Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M, Zurakowski A. Effect of chitosan in complex management of obesity. Pol Merkuriusz Lek 2002;13:129–32
- "A non-prescription alternative in weight reduction therapy " Conte AA. Am J Bariatr Med. Summer 1993:17-19
- Dietary Supplements and Functional Foods; July 11, 1995; Las Vegas, NV.
2. Schiller RN et al. A randomized, double blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. JANA. 4(1):42-9, 2001.
3. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Biosci Biotechnol Biochem. 1995 May;59(5):786-90.
- Nauss J L, et al, "The Binding of Micellar lipids to Chitosan," Lipids 18 (10). 1983. 714-719 Chitosan absorbs 4-6 times its own weight in fat
- Nauss JL, Thomson JL, Nagyuvary Y et al. The binding of micellar lipids to chitosan. Lipids. 1983; 18:246-7.
- Deuchi K, Kanauchi O, Imasato Y, et al. Decreasing effect of chitosan on the apparent fat digestibility by rats fed on a high-fat diet. Biosci Biotech Biochem 1994;58:1613–6.
- Kanauchi O, Deuchi K, Imasato Y, et al. Increasing effect of a chitosan and ascorbic acid mixture on fecal dietary fat excretion. Biosci Biotech Biochem 1994;58:1617–20.
4. Sakkinen M, Marvola J, Kanerva H, Lindevall K, Lipponen M, Kekki T, Ahonen A, Marvola M. Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. Division of Biopharmaceutics and Pharmacokinetics, Department of Pharmacy, University of Helsinki, Helsinki, Finland. mia.sakkinen@helsinki.fi Eur J Pharm Biopharm. 2004 Jan;57(1):133-43.
5. Sciutto AM, Colombo P. Lipid-lowering effect of chitosan dietary integrator and hypocaloric diet in obese subjects. Acta Toxicol Ther. 1995; 16:215-30.
- Veneroni G, Veneroni F, Contos S et al. Effect of a new chitosan dietary integrator and hypocaloric diet on hyperlipidemia and overweight in obese patients. Acta Toxicol Ther. 1996; 16:53-70.
- Colombo P, Sciutto AM. Nutritional aspects of chitosan employment in hypocaloric diet. Acta Toxicol Ther. 1996; 16:287-302.
6. Razdan, A., et al., "Broiler chicken body weights, feed intakes, plasma lipid and small-intestinal bile acid concentrations in response to feeding of chitosan and pectin," Br J Nutr, 78(2):283-91 1997 Aug
7. Mattioli-Belmonte M, Muzzarelli B, Muzzarelli RAA. Chitin and chitosan in wound healing and other biomedical applications. Carbohydr Eur 1997(19Dec):30-36.
- Muzzarelli RAA, Biagini G. Role and fate of exogeneous chitosans in human wound tissues. Ed Chitin Enzymology, Eur Chitin Soc 1993, Ancona.
8. Chitin : A Natural Product for the 21st Century, International Commission on Natural Health Products, 1995.
- DerMarderosian A, Beutler JA, eds. Facts and comparisons: the review of natural products. St. Louis: Wolters Kluwer; 2002.
- Borchard, G and Junginger H.E., Modern drug delivery applications of chitosan. Adv Drug Del Rev., 52 (2): 103, 2001.
-Shigemasa Y, Minami S. Applications of chitin and chitosan for biomaterials. Biotechnol Gen Eng Rev 1995;13:383-420.
- Chandy, T. Sharma, C.P. "Chitosan - as a biomaterial biosurface technology division," Sree Chita Triunal Institute for Medical Sciences and Technology, Poojandrum, India. 1990
9. Macchi G. A new approach to the treatment of obesity: chitosan's effect on body weight reduction and plasma cholesterol levels. Acta Toxicol Ther. 1996; 16:303-20.
- Chiang, M.T., et al., "Effect of dietary chitosans with different viscosity on plasma lipids and lipid peroxidation in rats fed on a diet enriched with cholesterol," Biosci Biotechnol Biochem, 64(5):965-71 May 2000
- Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M, Zurakowski A. Effect of chitosan in complex management of obesity Pol Merkuriusz Lek. 2002 Aug;13(74):129-32.
10. Muzzarelli RA. Clinical and biochemical evaluation of chitosan for hypercholesterolemia and overweight control. In: Jolles P, Muzzarelli RA, eds. Chitin and chitinases. Basel, Switzerland: Birkhäuser; 1999:293-304.
- Tai TS, Sheu WH, Lee WJ, Yao HT, Chiang MT. Effect of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects with hypercholesterolemia.
Diabetes Care. 2000 Nov;23(11):1703-4.
- Maezaki Y, Tsuji K, Nakagawa Y et al. Hypocholesterolemic effect of chitosan in adult males. Biosci Biotech Biochem. 1993; 57:1439-44.
- Chitosan for weight loss and cholesterol management. Shields KM, Smock N, McQueen CE, Bryant PJ. Am J Health Syst Pharm. 2003 Jul 1;60(13):1310-2, 1315-6.
- Ylitalo R, Lehtinen S, Wuolijoki E, Ylitalo P, Lehtimaki T Cholesterol-lowering properties and safety of chitosan. Arzneimittelforschung 2002;52(1):1-7-2
- Lee JK, Kim SU, Kim JH. Modification of chitosan to improve its hypocholesterolemic capacity. Biosci Biotechnol Biochem. 1999 May;63(5):833-9.
11. Dunstan DW, Daly RM, Owen N, Jolley D, De Courten M, Shaw J, Zimmet P. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002; (10): 1729-36.
12. Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA. 2003; 290(10): 1323-30.
13. Slentz CA, Duscha BD, Johnson JL, Ketchum K, Aiken LB, Samsa GP, Houmard JA, Bales CW, Kraus WE. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study. Arch Intern Med. 2004; 164(1): 31-9.
- Lafortuna CL, Resnik M, Galvani C, Sartorio A. Effects of non-specific vs individualized exercise-training protocols on aerobic, anaerobic and strength performance in severely obese subjects during a short-term body mass reduction program. J Endocrinol Invest. 2003; 26(3): 197-205.
14. Kim KW, Thomas RL, Lee C, Park HJ. Antimicrobial activity of native chitosan, degraded chitosan, and O-carboxymethylated chitosan. J Food Prot. 2003 Aug;66(8):1495-8.
- Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity of chitin and its derivatives. Vaccine 1984;2:93-99.
- Choi BK, Kim KY, Yoo YJ, Oh SJ, Choi JH, Kim CY. In vitro antimicrobial activity of a chitooligosaccharide mixture against Actinobacillus actinomycetemcomitans and Streptococcus mutans. Int J Antimicrob Agents 2001;18:553-557
- Fujiwara M, Hayashi Y, Ohara N. Inhibitory effect of water-soluble chitosan on growth of Streptococcus mutans. New Microbiol. 2004 Jan;27(1):83-6.
- Zochina, Z.M. et al. "Inhibition of Chitosan of infection of t-series bacteriophages in the escherichia coli," Mikrobiologia, 1995 March/April: 64 (2) 211-5
- Tsai GJ, Zhang SL, Shieh PL. Antimicrobial activity of a low-molecular-weight chitosan obtained from cellulase digestion of chitosan. J Food Prot. 2004 Feb;67(2):396-8.
- Zivanovic S, Basurto CC, Chi S, Davidson PM, Weiss J. Molecular weight of chitosan influences antimicrobial activity in oil-in-water emulsions. J Food Prot. 2004 May;67(5):952-9.
- Choi BK, Kim KY, Yoo YJ, Oh SJ, Choi JH, Kim CY. In vitro antimicrobial activity of a chitooligosaccharide mixture against Actinobacillus actinomycetemcomitans and Streptococcus mutans. Int J Antimicrob Agents 2001;18:553-557
15. Jing SB, Li L, Ji D, Takiguchi Y, Yamaguchi T. Effect of chitosan on renal function in patients with chronic renal failure.
J Pharm Pharmacol. 1997 Jul;49(7):721-3.
16. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev. 1998;56(9):266-270.
- Hoeger WW. et al. Four-week supplementation with a natural dietary compound produces favorable changes in body composition. Adv. Ther. 1998; 15:305-314.
- Kaats GR, Fischer JA, Blum K. The effects of chromium picolinate supplementation on body composition in different age groups [abstract]. Am Aging Assoc Abstr 1991; 21: 138.
- Stearns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995; 9: 1650-1657.
- Anderson RA. Effects of chromium on body composition and body weight. Nutr Rev 1998; 56: 266-270.
- Schardt, D. and Schmidt, S. (1996) "Supplement Watch: Chromium." Nutrition Action Healthletter, May, 10-11
- Kaats GR. et al. A randomized double blind placebo controlled study of the effects of chromium picolinate supplementation on body composition. Curr. Ther. Res. Clin. Exp. 1998; 59:379-388.
- Kaats GR. et al. Effects of chromium picolinate supplementation on body composition: A randomized double blind placebo controlled study. Curr. Ther. Res. 1996; 57:747-756.
17. Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc 1997; 29: 992-998.
- Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr. 1996;63(6):954-965.
- Campbell WW, Beard JL, Joseph LJ, Davey SL, Evans WJ. Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. Am J Clin Nutr. 1997;66(4):944-949.
- Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr. 2001;20(4):293-306.
18. Anderson RA, Cheng N, Bryden N, et aI. Beneficial effects of chromium for people with diabetes. Diabetes, May, 1966;45 (supple 2]: Abstract 1263.
- William T. Cefalu, Audrey D. Bell-Farrow, Jane Stegner, Zhong Q. Wang, Telle King, Tim Morgan and James G. Terry. Effect of chromium picolinate on insulin sensitivity in vivo, Journal of Trace Elements in Experimental Medicine 12:17-83, 1999
- Abraham AS, Brooks BA and Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin dependent diabetes. Metabolism, July 1992; 7:768.
- Anderson RA, Polansky MM, Bryden NA, et. al. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr, 1991; 54:909-16.
- Anderson RA and Kozlowsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. American J of Clinical Nutrition, 1985; 41 :1177.
- Evans GW, “Chromium picolinate is an efficacious and safe supplement”. Int J Sport Nutr 3, 117-122, 1993
19. Anderson JW, Allgood LD, Turner J, et al. Effects of psyllium on glucose and serum lipid response in men with type 2 diabetes and hypercholesterolemia. Am J Clin Nutr 1999;70:466-73.
- Rodriguez-Moran M, Guerrero-Romero F, Lazcano-Burciaga G. Lipid- and glucose-lowering efficacy of plantago psyllium in type II diabetes. J Diabetes Complications 1998;12:273-8.
20. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000;71:472–9.
- Oson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: Results of a meta-analysis. J Nutr 1997;127:1973-80.
- Anderson JW, Davidson MH, Blonde L, et al. Long-term cholesterol-lowering effects as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 2000;71:1433-8.
21. Davidson MH, Dugan LD, Burns JH, et al. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: A controlled, double-blind, crossover study. Am J Clin Nutr 1996;63:96-102.
22. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999;94:427-33.
23. Biancardi G, Palmiero L, Ghirardi PE. Glucomannan in the treatment of overweight patients with osteoarthritis. Curr Ther Res 1989;46:908–12.
24. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Med 1992;83:135–9 [in Italian].
- Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289–93.
- Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr 1995;61:585–9.
25. Livieri C, Novazi F, Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir 1992;14:195–8 [in Italian].
- Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol 1993;28:133-6.
26. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913-9.
- Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995;49(Suppl. 3):S190-7 [review].
- Doi K, Matsuura M, Kawara A, Baba S. Treatment of diabetes with glucomannan (konjac mannan). Lancet 1979;1:987-8 [letter].
- Melga P, Giusto M, Ciuchi E, et al. Dietary fiber in the dietetic therapy of diabetes mellitus. Experimental data with purified glucomannans. Riv Eur Sci Med Farmacol 1992;14:367-73 [in Italian].
- Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. Minerva Ginecol 1990;42:271-4 [in Italian].
- Huang CY, Zhang MY, Peng SS, et al. Effect of Konjac food on blood glucose level in patients with diabetes. Biomed Environ Sci 1990;3:123-31.
- Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. Minerva Ginecol 1990;42:271-4 [in Italian].
- Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9-14.
- Kneepkens CM, Fernandes J, Vonk RJ. Dumping syndrome in children. Diagnosis and effect of glucomannan on glucose tolerance and absorption. Acta Paediatr Scand 1988;77:279-86.
27. Passaretti S, Franzoni M, Comin U, et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Ital J Gastroenterol 1991;23:421-5.
- Staianno A, Simeone D, Giudice ED, et al. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. J Pediatr 2000;136:41-5.
- Marzio L, Del Bianco R, Donne M, et al. Mouth-to-cecum transit time in patients affected by chronic constipation: Effect of glucomannan. Am J Gastroenterol 1989;84:888-91.
- Marsicano LJ, Berrizbeitia ML, Mondelo A. Use of glucomannan dietary fiber in changes in intestinal habit G E N 1995;49:7-14
28. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr 1992;56:1061-5.
29. Todd PA, Befield P, Goa KL. Guar gum: a review of its pharmacological properties and use as a dietary adjunct in hypercholesterolemia. Drugs 1990;39:917-28.
30. Miyasaka A, Imoto T. Electrophysiological characterization of the inhibitory effect of a novel peptide gurmarin on the sweet taste response in rats. Brain Res. 1995 Apr 3;676(1):63-8.
- Ray A, Birch GG. Time dependent inhibition of sucrose sweetness with gymnemic acid: mode of action. Life Sci,
1981;28:2773-2781
- Meiselman HL, Halpern BP. Effects of Gymnema sylvestre on complex tastes elicited by amino acids and sucrose. Physiol
Behav, 1970;5:1379-1384
- Fushiki T, Kojima A, Imoto T, Inoue K, Sugimoto E. An extract of Gymnema sylvestre leaves and purified gymnemic
acid inhibits glucose stimulated gastric inhibitory peptide secretion in rats. J Nutr, 1992;122:2367-2373
- Shimizu K, Abe T, Nakajyo S, Urakawa N, Atsuchi M, Yamashita C. Inhibitory effects of glucose utilization by gymnema acids in the guinea-pig ileal longitudinal muscle. J Smooth Muscle Res. 1996 Oct;32(5):219-28.
- Shimizu K, Iino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi M, Wada T, Yamashita C. Suppression of glucose absorption by some fractions extracted from Gymnema sylvestre leaves. J Vet Med Sci. 1997 Apr;59(4):245-51.
- Shimizu K, Ozeki M, Tanaka K, Itoh K, Nakajyo S, Urakawa N, Atsuchi M. Suppression of glucose absorption by extracts from the leaves of Gymnema inodorum. J Vet Med Sci. 1997 Sep;59(9):753-7.
- Warren RP, Warren RM, Weninger MG. Inhibition of the sweet taste by Gymnema sylvestre. Nature, 1969;223:94-95
- Kurihara Y. Antisweet activity of gymnemic acid A1 and its derivatives. Life Sci, 1969;8:537-543
- Ota M, Shimizu Y, Tonosaki K, Ariyoshi Y. Role of hydrophobic amino acids in gurmarin, a sweetness-suppressing polypeptide. Biopolymers. 1998 Mar;45(3):231-8.
- Ota M, Shimizu Y, Tonosaki K, Ariyoshi Y. Synthesis, characterization, and sweetness-suppressing activities of gurmarin analogues missing one disulfide bond. Biopolymers. 1998 Aug;46(2):65-73.
- Suttisri R, Lee IS, Kinghorn AD. Plant-derived triterpenoid sweetness inhibitors. J Ethnopharmacol. 1995 Jun 23;47(1):9-26.
31. Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990 Oct;30(3):281-94.
- Murakami N, Murakami T, Kadoya M, Matsuda H, Yamahara J, Yoshikawa M. New hypoglycemic constituents in "gymnemic acid" from Gymnema sylvestre. Chem Pharm Bull (Tokyo). 1996 Feb;44(2):469-71.
- Chattopadhyay RR. Possible mechanism of antihyperglycemic effect of Gymnema sylvestre leaf extract. Gen Pharmacol. 1998 Sep;31(3):495-6.
- Khare AK, Tondon RN, Tewari JP. Hypoglycaemic activity of an indigenous drug (Gymnema sylvestre, 'Gurmar') in normal and diabetic persons. Indian J Physiol Pharmacol. 1983 Jul-Sep;27(3):257-8.
- Srivastava Y, Nigam SK, Bhatt HV, Verma Y, Prem AS. Hypoglycemic and life-prolonging properties of Gymnema sylvestre leaf extract in diabetic rats. Isr J Med Sci. 1985 Jun;21(6):540-2.
- Yoshikawa M, Murakami T, Kadoya M, Li Y, Murakami N, Yamahara J, Matsuda H. Medicinal foodstuffs. IX. The inhibitors of glucose absorption from the leaves of Gymnema sylvestre R. BR. (Asclepiadaceae): structures of gymnemosides a and b. Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1671-6.
- Yoshikawa M, Murakami T, Matsuda H. Medicinal foodstuffs. X. Structures of new triterpene glycosides, gymnemosides-c, -d, -e, and -f, from the leaves of Gymnema sylvestre R. Br.: influence of gymnema glycosides on glucose uptake in rat small intestinal fragments. Chem Pharm Bull (Tokyo). 1997 Dec;45(12):2034-8.
32. Shanmugasundaram ER, Gopinath KL, Radha Shanmugasundaram K, Rajendran VM. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol. 1990 Oct;30(3):265-79.
33. Maebashi M, Kawamura N, Sato M, et al. Lipid-lowering effects of carnitine in patients with type-IV hypolipoproteinaemia. Lancet. 1978; 2:805-807.
- Rossi CS, Siliprandi N. Effects of carnitine on serum HDL-cholesterol: report of two cases. Johns Hopkins Medical J. 1982; 150:51-54.
34. Vacha GM, Giorcelli G, Siliprandi N, Corsi G. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr. 1983; 38:532-540.
35. Pola P, Savi L Grilli M, et al. Carnitine in the therapy of dyslipidemic patients. Curr Therapeu Res. 1980; 27:208-216.
36. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Department of Internal Medicine, University of Ulsan College of Medicine, 138-736 Poongnap-dong, Songpa-ku, Seoul 138-736, Korea.
37. "chitosan is a revolutionary discovery that reduces fat, lowers triglycerides helps raise good cholesterol and controls appetite naturally," says Dr.Arnold Fox, a noted Beverly Hills, Calif., cardiologist and author of the new book: The Fat Blocker Diet, St. Martin's Press.
38. Dr. Elizabeth Muss, assistant clinical professor at Cornell University Medical College in Ithaca, N.Y., says: "chitosan is a highly effective, safe, simple, and inexpensive way to lose fat.

39. Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity.Int J Obes Relat Metab Disord.2000 Feb;24(2):252-8.
40. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr. 1999; 70:1040-1045.

Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.